Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.

about

Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.

Item

http://www.wikidata.org/entity/Q35666515

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Predictors of Progression to H ...... cinoma in Barrett's Esophagus.

@ast

Predictors of Progression to H ...... cinoma in Barrett's Esophagus.

@en

type

Item

label

Predictors of Progression to H ...... cinoma in Barrett's Esophagus.

@ast

Predictors of Progression to H ...... cinoma in Barrett's Esophagus.

@en

prefLabel

Predictors of Progression to H ...... cinoma in Barrett's Esophagus.

@ast

Predictors of Progression to H ...... cinoma in Barrett's Esophagus.

@en

P1476

Predictors of Progression to H ...... cinoma in Barrett's Esophagus.

@en

P2093

Matthew J Whitson

http://www.w3.org/2001/XMLSchema#string

P2860

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma

Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis

Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence

Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk

Radiofrequency ablation in Barrett's esophagus with dysplasia

A segregation analysis of Barrett's esophagus and associated adenocarcinomas.

Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.

Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis

Body mass index, smoking, and alcohol and risks of Barrett's esophagus and esophageal adenocarcinoma: a UK prospective cohort study.

Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.

P304

299-315

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.GTC.2015.02.005

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gary W. Falk

P577

2015-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26021196

http://www.w3.org/2001/XMLSchema#string

P932

4449455

http://www.w3.org/2001/XMLSchema#string